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improved cardiac function.3,4 On the basis of the initial
success of cell transplantation with fetal cardiomyocytes,
transplantation of other types of cultured cells has also
been investigated, and some types have resulted in signif-
icant improvement of cardiac function.5,6
There is, at present, only limited data comparing the
M olecular and cellular biologic evidence offer thepromise of new therapeutic approaches to heart
failure. Cell transplantation has recently been advocat-
ed as a means to repair failing hearts.1,2 In animal models,
cultured fetal cardiomyocytes have been successfully
transplanted into ischemic myocardium, which resulted in
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degree of improvement in heart function that can be
achieved by the transplantation of various cell types,
because published reports have examined only individ-
ual cell types. No study has yet identified the cell type
that may offer superior functional augmentation or
whether cardiomyocytes are more effective than other
cell types. In addition, the mechanisms by which trans-
planted cells may enhance ventricular function have not
been fully investigated. 
The purpose of our study was therefore to assess the
relative merits of cardiomyocytes for cell transplanta-
tion and to address some possible mechanisms of the
fuctional improvement noted after cell transplantation.
We compared 3 different fetal rat cell types: ventricular
cardiomyocytes, enteric smooth muscle cells (as non-
striated muscle cells), and skin fibroblasts (as noncon-
tractile cells).
Material and methods
Experimental animals. The Animal Care Committee of
The Toronto Hospital approved all experimental procedures,
which were preformed according to the “Guide to the Care
and Use of Experimental Animals” of the Canadian Council on
Animal Care and the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources, National Research Council, and published
by the National Academy Press, revised 1996. Nineteen-day
fetuses were harvested as cell donors from dated pregnant
Sprague-Dawley rats (Lewis; Charles River Canada Inc,
Quebec, PQ, Canada). Adult male Sprague-Dawley rats weigh-
ing 300 to 350 g served as cell transplantation recipients.
Cell culture and preparation for transplantation.
Ventricular cardiomyocytes, gastric smooth muscle cells, and
skin fibroblasts were isolated and cultured by methods we
have previously described.7 In brief, for cardiomyocytes, the
fetal hearts were washed 3 times in phosphate-buffered saline
solution (PBS; NaCl, 136.9 mmol/L; KCl, 2.7 mmol/L;
Na2HPO4, 8.1 mmol/L; and KH2PO4, 1.5 mmol/L; pH 7.3).
After the atria and great vessels were removed, the ventricles
were minced with fine scissors and incubated in PBS solution
containing trypsin (0.5%), collagenase (0.1%), and glucose
(0.02%) at 37°C. Smooth muscle cells from the stomach and
skin fibroblasts were also processed as described. Digestion
with trypsin and collagenase was performed for 10 minutes
for cardiomyocytes and for 30 minutes for smooth muscle
cells and fibroblasts. The clumps of cells were separated by
gentle agitation during the digestion. The cell suspension was
transferred into a tube containing 20 mL of culture medium
supplemented with 10% fetal bovine serum, 100 U/mL of
penicillin, and 100 m g/mL of streptomycin. Iscove’s modified
Dulbecco’s medium (Gibco Laboratory, Life Technologies,
Grand Island, NY) containing 0.1 mmol/L b -mercaptoethanol
was used for cardiomyocytes. Dulbecco’s modified Eagle’s
medium (Sigma Chemical Co, St Louis, Mo) was used for
smooth muscle cells and fibroblasts. The cell suspension was
centrifuged at 600g for 5 minutes, and the cell pellet was
resuspended in culture medium. At this stage, cardiomyo-
cytes were purified by a preplating method.7 The freshly iso-
lated myocardial cells were plated on dishes and cultured 2
hours to let noncardiomyocytes attach to the surface of the
dishes. Then the supernatant containing floating cardiomyo-
cytes was transferred into another dish for further culture.
The isolated cells were cultured at 37°C in 5% carbon diox-
ide and 95% air. Twenty-four hours after seeding, the cells
were detached from the culture dishes with 1 mL of 0.05%
trypsin in PBS solution with glucose (0.02%). The reaction
was stopped by the addition of culture medium, and the cell
suspension was then centrifuged at 600g for 5 minutes. The
cell pellet was resuspended in culture medium at a concen-
tration of 1.6 · 107 cells/mL. A volume of 0.25 mL of the cell
suspension was used for each transplantation.
Cell purity
Cardiomyocytes. The cultured cardiomyocytes beat sponta-
neously and regularly at a rate of 67 to 70 beats/min in the
culture dishes. At the time of transplantation, the purity of the
cardiomyocytes in culture was evaluated by staining with a
monoclonal antibody against myosin heavy chain (Rougier
Bio-Tech Ltd, Quebec, Canada), with a technique that we
have previously described.7
Smooth muscle cells. The purity of the smooth muscle cells
in culture was evaluated with a monoclonal antibody against
alpha–smooth muscle actin (Sigma Diagnostics, St Louis,
Mo). In brief, the cells were washed with PBS and fixed in
100% methanol at –20°C for 15 minutes. After being washed
with PBS 3 times, the cells were incubated with the first anti-
body against smooth muscle cell actin at 37°C for 30 minutes
followed by an overnight incubation at 4°C. The control sam-
ple was incubated with PBS. After samples were washed with
PBS (3 times, for 5 minutes each), a biotin-labeled secondary
antibody (1:250; Ector Lab Inc, Burlingame, Calif) was
added to the specimens and incubated at room temperature
for 1 hour. The samples were rinsed 3 times for 5 minutes
each in PBS and incubated with an avidin-biotin complex
conjugated with peroxidase at room temperature for 45 min-
utes. Visualization was accomplished with diaminobenzine
solution (0.25 mg/mL in 0.05 Tris-HCl buffer containing
0.02% H2O2) for 10 minutes. The cellular nuclei were coun-
terstained with hematoxylin for 1 minute. The samples were
covered with crystal mounts and photographed.
Fibroblasts. Fibroblasts were identified morphologically
by light microscopy by their characteristic spindle-shaped
appearance.
Anesthesia and postoperative care of the recipients rats.
Adult male rats were anesthetized with an intramuscular
injection of ketamine hydrochloride (22 mg/kg), followed by
an intraperitoneal injection of sodium pentobarbital (30
mg/kg). The rats were endotracheally intubated and ventilat-
ed with a Harvard ventilator (model 683; Harvard Apparatus
Co, Inc, S Natick, Mass). Positive-pressure ventilation was
maintained at a rate of 60 cycles/min with a tidal volume of
3 mL with room air supplemented with oxygen (2 L/min).
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Penlong XL (penicillin G benzathine, 150,000 U/mL, and
penicillin G procaine, 150,000 U/mL) was injected intramus-
cularly (0.4 mL per rat). Buprenorphine hydrochloride (0.01
mg/kg body weight) was given subcutaneously every 8 hours
for the first 48 hours after the operation. After the operation,
rats were monitored until they fully recovered from the anes-
thesia and were then returned to their cages.
Myocardial scar formation. After the rat received gener-
al anesthesia as described, the heart was exposed through a 2-
cm left lateral thoracotomy. An 8- · 10-mm metal probe was
cooled to –190°C by immersion in liquid nitrogen and was
applied with gentle pressure on the left ventricular free wall
to produce a cryoinjury. After 1 minute, the cryoprobe was
removed from the surface of the heart and immersed in liquid
nitrogen. When the frost on the cryoinjured area of the heart
had disappeared, the cryoprobe was reapplied to the same
area of the heart. This procedure was performed a total of 10
times. Our previous study has shown that cryoinjury generat-
ed a scar comprising 36% ± 4% of the left ventricular free
wall at 4 weeks. At 8 weeks, the scar had expanded to 55% ±
3% of the left ventricular free wall.3
Cell transplantation. Four weeks after cryoinjury, rats
were randomly assigned either to a cell-transplantation group
or to a control group. Rat hearts were exposed with a median
sternotomy after general anesthesia was administered. In the
transplantation groups (cardiomyocytes, n = 13; smooth mus-
cle cells, n = 10; fibroblasts, n = 10), 0.25 mL of cells sus-
pended in culture medium (4 · 106 cells) was injected into the
center of the scar tissue of the left ventricular free wall with
a tuberculin syringe. In control rats (total number = 15; 5 con-
trol rats for each cell type), the same volume of culture medi-
um was injected into the scar in the same manner. All the rats
received daily subcutaneous injections of cyclosporine A
(INN: ciclosporin), at a dose of 5 mg/kg body weight per day.
Myocardial function study. Four weeks after transplanta-
tion, heart function of the transplanted and control rats was
evaluated in a Langendorff preparation.8 After general anes-
thesia was administered, heparin sodium (200 units) was
administered intravenously to the rats. With a repeated ster-
notomy, the heart was quickly excised and perfused in a
Langendorff apparatus with filtered Krebs-Henseleit buffer
(NaCl, 118 mmol/L; KCl, 4.7 mmol/L; KH2PO4, 1.2
mmol/L; CaCl2, 2.5 mmol/L; MgSO4, 1.2 mmol/L; NaHCO3,
25 mmol/L; glucose, 11 mmol/L; pH 7.4) equilibrated with
5% carbon dioxide and 95% oxygen. A latex balloon was
inserted into the left ventricle through the mitral valve and
connected to a pressure transducer (model p10EZ; Viggo-
Spectramed, Oxnard, Calif), a transducer amplifier, and a
differentiation amplifier (model 11-G4113-01; Gould
Instrument System, Inc, Valley View, Ohio). After 30 minutes
of stabilization at 37°C, coronary flows were measured by
repeated timed collections. Balloon volume was adjusted to
produce an end-diastolic pressure of –25 mm Hg, which was
set as the baseline. The balloon size was then increased in
0.02 mL increments from 0.04 mL to 0.48 mL by the step-
wise addition of saline solution. Systolic and diastolic pres-
sure, the maximal rate of myocardial contraction (+dP/dt
max
),
and the maximal rate of myocardial relaxation (–dP/dt
max
)
were recorded at each balloon volume, and the developed
pressure was calculated as the differences between the peak-
systolic and the end-diastolic pressures. After the measure-
ments were completed, the heart was arrested with 10 mL
infusion of a 20% KCl solution into the aortic root.
Measurement of left ventricular remodeling. After the
heart was arrested, we measured the ventricular volumes as
described by Pfeffer and associates.9 The volume of the intra-
ventricular balloon required to distend the arrested left ven-
tricle to a pressure of 30 mm Hg was recorded. The heart was
then fixed with 10% phosphate-buffered formalin solution in
a distended state. Two days after fixation, the balloon was
removed, and the atria and great arteries were excised. The
heart was weighed. The epicardial and the endocardial sur-
face areas of the left ventricular free wall and those of the cry-
oinjury-derived scar tissue were measured by planimetry as
previously described.3 In brief, the heart was cut into 5 slices
each 3-mm thick. The areas and lengths of interest were
traced and quantified by computed planimetry (Jandal
Scientific Sigma-Scan, Corte Madera, Calif). The total endo-
cardial and epicardial surface area of the scar tissue was mea-
sured as the sum of the epicardial length and the endocardial
length · the thickness (3 mm).
For comparisons between the 3 transplantation groups, “the
left ventricular volume index,” “the scar area index,” and “the
scar thickness index” were used. The left ventricular volume
index was defined as the left ventricular volumes of each trans-
plantation group divided by the mean left ventricular volumes
of their control rats. The scar area index was defined as the
percent scar area of the left ventricular free wall of each trans-
plantation group by the mean percent scar area of the left ven-
tricular free wall of each transplantation group by the mean
percent scar area wall of its control group. The scar thickness
index was calculated by dividing the scar thickness of the trans-
plantation group by the mean scar thickness of its control
group. In addition, the percentage of the area of the myocardial
scar occupied by the transplanted cells was recorded.
Histologic studies. The heart sections were fixed in 5%
glacial acetic acid in methanol, embedded in paraffin, and
sectioned to produce 10-m m thick specimens. The sections
were stained with hematoxylin and eosin as described in the
manufacturer’s specifications (Sigma Diagnostics).
Data analysis. All data are expressed as the mean ± the
standard deviation. The heart rate, coronary flow, heart
weight, left ventricular volume index, scar area index, scar
thickness index, and percentage of scar area occupied by
transplanted cells were analyzed with the SPSS software
package for Windows v8.0 (SPSS Inc, Chicago, Ill). Com-
parisons of continuous variables among the 3 groups were
performed by a 1-way analysis of variance, and Scheffé’s test
was used to specify differences among groups. 
Functional data were evaluated with the SAS software
package for Windows v6.12 (SAS Institute Inc, Cary, NC).
To compare the results of different studies, we carefully
indexed the results from each transplantation group to its
own control group and expressed the results as the differ-
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ence from control (end-diastolic pressure) or percent difference
from control (developed pressure, +dP/dt
max
, and –dP/dt
max
).
The 3 transplantation groups were compared by analysis of
covariance, with intraventricular balloon volume as the
covariate and developed pressure index, end-diastolic pres-
sure index, +dP/dt
max
index, and –dP/dt
max
index as depen-
dent variables. Main effects were group, volume, and inter-
action of group · volume. If a significant difference was
identified among groups by analysis of covariance, pair-wise
comparisons were performed to specify differences.
Results
Cryoinjury model. The rat mortality rate in the
process of scar generation was 2%.
Ventricular function. There were no significant dif-
ferences in heart rate, coronary flow, or heart weight
among the 3 groups (Table I).
Developed pressure (expressed as a percentage of
control values) was significantly greater in the car-
diomyocyte group than in the smooth muscle cell
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Table I. Heart rate, coronary flow, and heart weight at the time of functional study
Cardiomyocytes Smooth muscle cells Fibroblasts P value
Heart rate (beats/min) 400.0 ± 28.4 351.0 ± 47.0 361.0 ± 43.6 .12
Coronary flow (mL/min) 19.4 ± 1.9 21.3 ± 3.4 18.6 ± 2.3 .12
Heart weight (g) 1.60 ± 0.08 1.68 ± 0.34 1.55 ± 0.15 .46
A B
C D
Fig 1. Indices of (A) developed pressure, (B) +dP/dt
max
, (C)–dP/dt
max
, and (D) end-diastolic pressure in hearts
transplanted with cardiomyocytes (CM), smooth muscle cells (SM), and fibroblasts (FB) at intraventricular bal-
loon volumes of 0.1 and 0.2 mL. By analysis of covariance, the indices of developed pressure, +dP/dt
max
, and
–dP/dt
max
in cardiomyocytes were significantly greater than in smooth muscle cell and fibroblast (**P = .0001).
Smooth muscle cell had significantly greater +dP/dt
max
index and –dP/dt
max
index than fibroblast (*P = .0024,
.014, respectively), but there was not a significant difference in developed pressure index (P = .63). There were
no significant differences in end-diastolic pressure index (P = .22).
group or the fibroblast group (P = .0001), although
there was no significant difference between the smooth
muscle cell and fibroblast groups (P = .63; Fig 1, A).
The +dP/dt
max
(expressed as a percentage of control
values) was significantly higher in cardiomyocyte
group than in the other groups (P = .0001), and smooth
muscle cell group was higher than fibroblast group (P
= .0024; Fig 1, B).
The –dP/dt
max
(expressed as a percentage of control
values) was significantly greater in the cardiomyocyte
group than in the other groups (P = .0001), and smooth
muscle cell group was greater than fibroblast group (P
= .014; Fig 1, C).
The end-diastolic pressures (expressed as differences
from their control values) were not significantly differ-
ent among the 3 groups (P = .22; Fig 1, D).
Histologic studies. The purity of the cultured cells,
evaluated by immunohistochemstry, was 94.0% ± 3.5%
for the fetal rat cardiomyocytes and 86.0% ± 5.3% for
the fetal rat smooth muscle cells. Fibroblasts tended to
grow easily and quickly, resulting in greater than 95%
purity.
All the transplanted cells formed a block of tissue in
the myocardial scar. Photomicrographs of the trans-
planted hearts showed a characteristic morphologic
condition for each cell type, with infiltration of lym-
phocytes around the transplanted cells in spite of the
administration of cyclosporine A. All the transplanted
cells were completely surrounded by host scar tissue. A
number of capillaries were seen in the area of trans-
plantation, for all cell types. The transplanted fetal car-
diomyocytes formed striated myocardium. The align-
ment of the tissue formed by the transplanted
cardiomyocytes appeared to be somewhat disorga-
nized, compared with the native myocardium (Fig 2, A
and B). This tissue, when excised en bloc, appeared to
beat spontaneously and regularly at the time of explan-
tation. The transplanted fetal smooth muscle cells (Fig
3, A and B) stained positively with antibodies against
smooth muscle actin (Fig 3, C). The transplanted fetal
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Fig 2. Fetal cardiomyocyte transplantation. Transplanted cardiomyocytes formed cardiac tissue (T) in the myocar-
dial scar tissue (S). L, Lymphocytes; H, host myocardium. (Hematoxylin and eosin stain; original magnifications:
A, · 100; B, · 400.)
A B
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A
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Fig 3. Fetal smooth muscle cell transplantation. (Hematoxylin and eosin stain; original magnifications: A, · 40;
B, · 400.) Transplanted smooth muscle cells formed tissue (T), which were stained positively for smooth muscle
specific actin (C, · 400; arrows). S, Myocardial scar; L, lymphocytes.
fibroblasts formed a dense fibrous structure with what
appeared to be hair follicles (Fig 4). The transplanted
smooth muscle cells and fibroblasts within the scar tis-
sue did not align normally. The control group, which
had been injected only with culture medium but no
cells, had a thin layer of fibrous scar (Fig 5).
Left ventricular remodeling. There were not statis-
tically significant differences in left ventricular volume
indices between groups (Table II). The scar thickness
index and the scar area index were significantly lower
in the cardiomyocyte transplantation group than in the
other 2 groups. In all of the transplanted groups, trans-
planted cells occupied more than 30% of the scar area.
The fibroblast transplantation group demonstrated the
greatest cell proliferation within the scar.
Discussion
Cell transplantation has been advocated as an alter-
native therapy to restore heart function after a myocar-
dial infarction. We3 and other investigators4 have found
that transplanted fetal cardiomyocytes improved heart
function in a rat model. We have reported improvement
in left ventricular function after transplantation of cul-
tured fetal enteric smooth muscle cells into the cryoin-
jury-induced scar tissue of rat hearts.5 Taylor and asso-
ciates6 demonstrated improved regional systolic and
diastolic function after transplantation of cultured
autologous skeletal satellite cells in a cryoinjured rab-
bit heart model. These findings support the effective-
ness of noncardiomyocyte cells for cell transplantation,
which may permit wider application of cell transplan-
tation techniques in the clinical setting.
The mechanisms of improvement of ventricular func-
tion after cell transplantation have not, however, been
fully elucidated. In addition, the effect of different cell
types on the functional outcome has not yet been
addressed. We hypothesized that cells with contractile
proteins, such as cardiomyocytes, may offer greater
functional recovery because of their elastic and con-
tractile properties.10 However, none of the published
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Fig 4. Fetal fibroblast transplantation. A dense fibrotic tissue (T) with hair follicles (arrows) was formed in the
myocardial scar (S). (Hematoxylin and eosin stain; original magnifications: A, · 40; B, · 400.)
A B
reports have demonstrated the significance of cells with
contractile proteins or any superiority of cardiomy-
ocytes over other cell types.
To address these issues, we transplanted 3 kinds of
fetal cells (cardiomyocytes, smooth muscle cells, and
fibroblasts) into the cryoinjured scar of rat hearts and
compared their functional outcomes and the left ven-
tricular remodeling process. We chose fetal cells
because of their superior growth potential compared
with adult or pediatric cells.11 Ventricular cardiomy-
ocytes served as a standard cell type, because the trans-
plantation of cardiomyocytes has been previously
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Table II. Left ventricular remodeling after cell transplantation
Cardiomyocytes Smooth muscle cells Fibroblasts
Left ventricular volume index* 1.00 ± 0.04 0.91 ± 0.32 0.84 ± 0.20
Scar thickness index 1.13 ± 0.25 2.10 ± 0.68† 2.40 ± 0.86†
Scar area index 0.78 ± 0.08 1.27 ± 0.28‡ 1.37 ± 0.34§
Transplantation area/scar areaII 37.0 ± 8.9 32.2 ± 4.8 51.3 ± 14.6¶
Each index was calculated as a ratio of control values.
*No significant difference (P = .44) by analysis of variance.
†P = .005, versus cardiomyocytes.
‡P = .023, versus cardiomyocytes.
§P = .003, versus cardiomyocytes.
IIPercentage of the area of scar tissue occupied by the transplanted cells.
¶P = .04, versus smooth muscle cells.
Fig 5. Control group. A thin fibrous cardiac scar was produced by cryoinjury. (Hematoxylin and eosin stain; orig-
inal magnifications: A, · 40; B, · 400.)
A B
reported to result in improvement in ventricular func-
tion. Smooth muscle cells derived from the stomach
were chosen as a nonstriated muscle cell with contrac-
tile proteins that differed from those of cardiomy-
ocytes. We did not use vascular smooth muscle cells
because of the difficulties in obtaining sufficient cells
from the great vessels of fetal rats. Skin fibroblasts
were selected as a cell with little, if any, contractile pro-
tein. We used a Langendorff perfusion model to assess
the heart function. Although this ex vivo method has
limitations compared with in vivo measurements by
echocardiography or conductance catheters, this tech-
nique was technically straightforward and allowed
identification of differences in systolic and diastolic
function between our 3 transplantations.
Histologic studies demonstrated that the transplanted
cells formed a block of tissue composed of their specif-
ic cell types in the myocardial scar. In a Langendorff
preparation, the cardiomyocyte transplantation group
had the greatest developed pressure, +dP/dt
max
, and
–dP/dt
max
. The smooth muscle cell transplantation
group had significantly better improvement than fibrob-
last transplanted hearts in +dP/dt
max
and –dP/dt
max
but
not in developed pressure. Fibroblast transplantation
resulted in the greatest scar thickness because of the
growth of the transplanted fibroblasts and a relatively
smaller left ventricular volume but showed the least
functional improvement in systolic function.
These observations may clarify some of the mecha-
nisms by which ventricular function is improved after
cell transplantation. A fundamental mechanism for this
functional improvement seems to be related to the law
of Laplace: t = Pr/w, where t is wall stress; P is trans-
mural pressure; r is radius, and w is wall thickness. All
the cell transplantation groups, including the fibroblast
transplanted rats, showed increased scar thickness and
relatively smaller left ventricular volumes than control
rats, which would decrease left ventricular wall stress
and contribute to this functional improvement. By this
mechanism, even noncontractile cells such as fibro-
blasts can offer some improvement.
A second mechanism seems to be related to the elas-
tic properties of the tissue formed by the transplanted
cells. Although transplanted fibroblasts formed the
thickest scar, they resulted in the least improvement in
function. The rigidity of the thick, fibrotic scar seen
after fibroblast transplantation may impair diastolic
ventricular filling. On the other hand, the tissue
formed by transplantation of cells with contractile pro-
teins (cardiomyocytes and smooth muscle cells) may
have greater elasticity, and this elasticity may partly
explain the greater improvement in function noted
after cardiomyocyte or smooth muscle cell transplan-
tation.
In this study, transplanted cardiomyocytes offered
significantly greater functional improvement than
smooth muscle cells. These observations are consistent
with those of Kumar and associates,12 who demonstrat-
ed the importance of cardiac-specific actin, compared
with the enteric smooth muscle–specific actin, in the
function and development of the heart.
In our study, the greater functional benefit of car-
diomyocytes over smooth muscle cells may be due to
the fact that the cardiomyocyte transplantation group
had significantly smaller scar areas than the smooth
muscle cell transplantation group. However, because
the scar thickness was greater in the smooth muscle
cell group and the left ventricular volume indexes were
identical between the 2 groups, the first potential mech-
anism, related to the law of Laplace, may not fully
explain this difference. Smooth muscle cells have been
reported to have passive characteristics, including
stress-length relationships, hyperbolic velocity-load
relationships, and power output curves and the ability
to resist imposed loads, similar to those of striated mus-
cle.13 The potential active contraction and relaxation of
transplanted cardiomyocytes may explain the differ-
ences noted between this group and the smooth muscle
cell-transplanted group. We have previously demon-
strated that fetal rat cardiomyocytes, when injected into
the subcutaneous tissue of rats, formed a block of tis-
sue that could be visualized grossly and by echocardio-
graphy beating at the rate of 73 ± 12 beats/min, 21 days
after injection.7 In this study, we found that the trans-
planted fetal cardiomyocytes formed a block of striated
myocardium and that this tissue, when excised en bloc,
appeared to beat spontaneously and regularly at the
time of explantation. To address this issue fully, how-
ever, further studies that use imaging modalities that
will permit evaluation of regional wall motion will be
required.
In conclusion, we transplanted 3 different fetal cell
types into the cryoinjury-induced myocardial scar of
rats. Cardiomyocyte transplantation offered the best
functional improvement, followed by smooth muscle
cell transplantation. Fibroblast transplantation had the
greatest effect on the left ventricular remodeling process
but resulted in minimal functional improvement. The
contractile and elastic properties of transplanted cells
determine the degree of improvement in ventricular
function achievable with cell transplantation.
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Discussion
Dr Juan C. Chachques (Paris, France). We are working in
a similar protocol using satellite cells (myoblasts), so I want
to ask you a technical question. If you perform Langendorff
hemodynamic studies, you cannot study the hearts histologi-
cally because the isolated beating heart at 37°C would have
histologic damage, making a histologic study impossible.
How did you perform in your protocol Langendorff studies
followed by histologic studies? 
Dr Sakai. Our studies of ventricular function in our
Langendorff preparation lasted about 45 minutes, during
which time the hearts were perfused with filtered Krebs-
Henseleit buffer solution equilibrated with 5% carbon dioxide
and 95% oxygen at 37°C. Because the hearts were well per-
fused, we did not anticipate significant histologic changes,
especially in the aspects we studied: identification of the
transplanted cells and their structure. We do not think that a
45-minute period of perfusion should affect these histologic
findings.
Dr Si M. Pham (Miami, Fla). It has been shown recently
that the nonhemopoietic stem cell from the bone marrow can
differentiate into different cells, myocytes, smooth muscle
cells, a variety of cells. Because it is difficult to grow the adult
cardiac myocytes. I wonder whether it would be more clini-
cally relevant if you can use some of those nonhemopoietic
stem cells from the bone marrow to inject it into the myocar-
dial scar? Have you done it or have you considered doing it? 
Dr Sakai. Immunorejection is a major problem in the
potential application of cell transplantation in a clinical set-
ting. The use of multipotential stem cells from autologous
bone marrow, and their induction to differentiate into car-
diomyocytes, is one of the several promising ways to avoid
immunorejection. Our research group has transplanted autol-
ogous bone marrow cells into a cryoinjured rat heart model.
In that study, we found that the transplanted bone marrow
cells survived in the scar tissue, limited scar expansion, and
improved heart function compared with a control group. In
our current study, we demonstrated the relative merits of fetal
cardiomyocytes, compared with other fetal cells, for cell
transplantation. It will be interesting to compare the func-
tional improvement after cardiomyocyte transplantation with
that with bone marrow cell transplantation.
Dr John E. Mayer, Jr (Boston, Mass). Other than histo-
logic appearance, what evidence do you have, if any, that the
cardiomyocytes are in fact really cardiomyocytes? Once they
get into the tissue, is there any evidence that they might
change their phenotype to become a different type of cell or is
there any evidence that they would change phenotype while
you were culturing them? The same questions, I think, would
apply for the smooth muscle cells and for the fibroblasts. It
sounds like the fibroblasts still remember how to make skin,
but I wondered if you had any other specific kinds of cell
markers that would help you with that kind of question? 
Dr Sakai. In our previous studies, we identified the cul-
tured cardiomyocytes by positive staining with antibodies
against troponin I and myosin heavy chain. We also found
that these cells expressed the myosin heavy chain gene in cul-
ture. Electron microscopy revealed myofilaments in the cells.
These cultured cardiomyocytes underwent marked time-
dependent dedifferentiation and lost the normal structure of
contractile proteins when they were maintained in cell culture
for up to 6 months. In the present study, however, the dura-
tion of cell culture was 24 hours, and the cultured cardiomy-
ocytes did not undergo significant phenotypic changes during
this period. After transplantation of cultured fetal cardiomy-
ocytes into the cryoinjured scar, electron microscopy showed
organized sarcomeres and intercalated discs in the transplant-
ed cardiomyocytes. The smooth muscle cells stained posi-
tively with an antibody against a -smooth muscle actin, both
in culture and in the tissue.
Dr Fred A. Crawford, Jr (Charleston, SC). You injected
these cells into a scar. Where did the blood supply come
from? How did they survive? 
Dr Sakai. We have studied angiogenesis in the scar area
where we transplanted cultured cardiomyocytes, smooth
muscle cells, fibroblasts, or endothelial cells. We found cap-
illaries and arterioles in the scar after transplantation of all of
these cell types. We speculate that this angiogenesis was
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stimulated by cell transplantation or by growth factors secret-
ed by the transplanted cells. It seemed that the vessels grew
inward from the surrounding myocardium.
Dr Jakob Vinten-Johansen (Atlanta, Ga). Have you done
studies to determine how long the myocytes retain their phe-
notype in the cryoinjured area? How long does the improve-
ment in function last? Have you done a time-course study and
determined whether functional recovery wanes after 8 weeks
or whether it continues or is maintained?
Dr Sakai. In our previous long-term study of fetal car-
diomyocyte transplantation, the tissue formed from allotrans-
planted cells gradually decreased in size over 24 weeks
because of immunorejection. The ventricular chamber size
increased with time compared with that at 4 weeks after
transplantation. The ventricular scar also became thinner.
These data suggested that allogenic cell transplantation was
unlikely to improve heart function in the long term. We have
focused on autologous cell transplantation to try to bypass
this problem. Transplantation of cultured autologous adult
cardiomyocytes and autologous bone marrow cells resulted in
survival of the transplanted cells and improvement of heart
function at 5 weeks after cell transplantation. We are currently
performing longer term studies of autologous cell transplan-
tation to determine the time course of this effect.
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